Caprock Group, Inc. Altimmune, Inc. Transaction History

Caprock Group, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2020 Apr 28, 2020	SELL	$1.69 - $3.8 $25,688 - $57,760	-15,200 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$1.53 - $2.15 $23,256 - $32,680	15,200 New	15,200 $29,000

191

42.4M

1.05M

582K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $301M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Caprock Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Caprock Group, Inc. with notifications on news.